Ulcerative colitis is an inflammatory bowel disease that severely impacts the quality of life. Sadly, it is not curable, but it can be managed with treatment. Salofalk is a drug that reduces inflammation in ulcerative colitis, and has been on the market for a long time.

Vifor Pharma has the Nordic distribution rights for the Dr Falk product range. It wanted to relaunch Salofalk with a new communicative style on the Nordic market.

We created a more modern visual profile, taking care not to detract from the already well-established brand’s recognition. Below are the two units we produced, a film for doctors, and a patient leaflet. All the material was translated and localised into four different languages.

Want to find out more about this project? Contact:
Berth Lindén
042-400 48 81

The film clearly illustrated Salofalk’s mechanism of action focusing on the granular form, which can be swallowed. The film was produced in association with Noam Briner.

Salofalk / Vifor Pharma
In the patient leaflet, we decided to use a soft, patient-friendly tone of voice. The leaflet is given to patients starting their treatment with Salofalk, describing the disease and the various dosage forms. The illustrations are by Oliver "Ollanski" Bieräugel.